2010;7:72-81. NCI CTCAE Version 5.0 (published in November 2017). Accessible at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Q uick_Reference_5x7.pdf. ClinicalTrials.gov identifier: NCT00398138 ClinicalTrials.gov identifier: NCT01266083 Clinical trial information: NCT02054806 Clinical trial information: NCT02359019 ClinicalTrials.gov identifier: NCT00665002 ClinicalTrials.gov identifier: NCT02737787 O’Cearbhaill RE, Gnjatic S, Aghajanian C, et al. A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission. ASCO 2018 Ann.